PDCD1 and melanoma: Another example is an off-the-shelf mRNA vaccine (BioNTech's BNT111) encoding fixed melanoma-associated antigens; in an early-phase trial, this vaccine plus a PD-1 inhibitor led to durable responses in some patients with refractory melanoma [113].